Has Pasqal grown their patent portfolio through organic growth or acquisition?
An IPO tells you the share price. It doesn't tell you who really invented what — or why Pasqal's own numbers don't quite add up.
Topic
news
A collection of 8 issues
Is Pictiva’s US$191 million win proof of enduring OLED innovation — or of effective IP monetisation?
On 4th November 2025, a Texas jury found that Samsung Electronics had infringed two US OLED patents owned by Pictiva Displays International, a subsidiary of Key Patent Innovations, which invests in and licenses high-value patent portfolios in emerging technology markets.
The Federal Court ordered Samsung to pay US$191.4
Quantum Technology Companies: patent analysis
Quantum computing patent applications have increased significantly since 2009, reflecting the growing maturity and industrial relevance of the field.
Patent intelligence for people who don't read patents
However, for those without a background in patents, or the means to access patent analytics, it’s not always clear what
Illumina's acquisition of Somalogic is a clear IP play
Illumina announced on 23 June 2025 that it will acquire SomaLogic from Standard BioTools, for US$350 million cash plus up to US$75 million in performance-based payments, reinforcing its multiomics roadmap by embedding high-plex proteomics into its sequencing operations. The transaction, expected to close in the first half of
Lilly hedges IP risk in $1.3bn Verve acquisition
Eli Lilly has announced its intention to acquire Verve Therapeutics for approximately US$1.3 billion, aiming to accelerate development of one-time gene-editing treatments for cardiovascular disease. The acquisition builds on a pre-existing collaboration between the two companies focused on in vivo gene editing and positions Lilly to compete more
2Seventybio to be acquired by Bristol Myers Squibb for US$286 million in cash deal
2Seventybio has announced a definitive merger agreement under which Bristol Myers Squibb (BMS) will acquire the company in an all-cash transaction for a total equity value of approximately US$ 286 million. The transaction has been approved by both companies and is expected to close in Q2 of this year.
2Seventybio
Jazz Pharmaceuticals acquires Chimerix for approximately US$935 million in cash
Through the acquisition Jazz Pharmaceuticals gains access to dordaviprone, a novel small molecule therapy in development for H3 K27M-mutant diffuse glioma in children and young adults. The transaction has been approved by both companies and is expected to close in Q2 of this year.
The acquisition sees Jazz Pharmaceuticals gain